![Egil Herman Sjursen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Egil Herman Sjursen
Directeur/Membre du Conseil chez Cytovation AS
Postes actifs de Egil Herman Sjursen
Sociétés | Poste | Début | Fin |
---|---|---|---|
Cytovation AS
![]() Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Egil Herman Sjursen
Anciens postes connus de Egil Herman Sjursen
Sociétés | Poste | Début | Fin |
---|---|---|---|
Holberg Fondsforvaltning AS
![]() Holberg Fondsforvaltning AS Investment ManagersFinance Holberg Fondsforvaltning AS (HF) is the wholly-owned fund management subsidiary of Norway-based Holberg Forvaltning AS, a holding company in which the founding partners are significant shareholders. Founded in 2000 by Gunnar J. Torgersen, Monica Mjøs Lassen, Inga Lise Lien Moldestad and Hogne I. Tyssøy, the firm is headquartered in Bergen and manages equity and fixed-income funds for individual and institutional investors. | Directeur Général | 01/10/2006 | 01/03/2018 |
Statistiques
Internationale
Norvège | 3 |
Opérationnelle
Chief Executive Officer | 1 |
Director/Board Member | 1 |
Sectorielle
Finance | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Holberg Fondsforvaltning AS
![]() Holberg Fondsforvaltning AS Investment ManagersFinance Holberg Fondsforvaltning AS (HF) is the wholly-owned fund management subsidiary of Norway-based Holberg Forvaltning AS, a holding company in which the founding partners are significant shareholders. Founded in 2000 by Gunnar J. Torgersen, Monica Mjøs Lassen, Inga Lise Lien Moldestad and Hogne I. Tyssøy, the firm is headquartered in Bergen and manages equity and fixed-income funds for individual and institutional investors. | Finance |
Cytovation AS
![]() Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | Commercial Services |
- Bourse
- Insiders
- Egil Herman Sjursen
- Expérience